{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fpodcast-celmods-in-lymphomas-nqIJ3lbY","width":444,"version":"1.0","type":"rich","title":"CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways ","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/4ef76b56-c86d-449f-944b-72271958664d/6931-lymphoma-celmod-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/61680e91-3061-4543-910f-c556c294d6f0\" height=\"200\" width=\"100%\" title=\"CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways \" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Julio C. Chavez, MD, MS, a medical oncologist based in an academic center, and Alan Skarbnik, MD, a medical oncologist based in the community, discuss the emerging role of CELMoDs in non-Hodgkin lymphoma care, including available data and ongoing clinical trials with these agents."}